DK3536333T3 - Depotsystem der omfatter glatirameracetat - Google Patents

Depotsystem der omfatter glatirameracetat Download PDF

Info

Publication number
DK3536333T3
DK3536333T3 DK18205308.2T DK18205308T DK3536333T3 DK 3536333 T3 DK3536333 T3 DK 3536333T3 DK 18205308 T DK18205308 T DK 18205308T DK 3536333 T3 DK3536333 T3 DK 3536333T3
Authority
DK
Denmark
Prior art keywords
system containing
glatiramer acetate
depot system
containing glatiramer
depot
Prior art date
Application number
DK18205308.2T
Other languages
Danish (da)
English (en)
Inventor
Ehud Marom
Shai Rubnov
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Application granted granted Critical
Publication of DK3536333T3 publication Critical patent/DK3536333T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Epoxy Resins (AREA)
  • Epoxy Compounds (AREA)
DK18205308.2T 2010-01-04 2010-08-19 Depotsystem der omfatter glatirameracetat DK3536333T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29192810P 2010-01-04 2010-01-04
EP10840699.2A EP2398488B1 (en) 2010-01-04 2010-08-19 Depot system comprising glatiramer acetate

Publications (1)

Publication Number Publication Date
DK3536333T3 true DK3536333T3 (da) 2022-10-24

Family

ID=44226217

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10840699.2T DK2398488T3 (en) 2010-01-04 2010-08-19 DEPOT SYSTEM INCLUDING GLATIR FRAME ACETATE
DK18205308.2T DK3536333T3 (da) 2010-01-04 2010-08-19 Depotsystem der omfatter glatirameracetat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10840699.2T DK2398488T3 (en) 2010-01-04 2010-08-19 DEPOT SYSTEM INCLUDING GLATIR FRAME ACETATE

Country Status (20)

Country Link
US (1) US8796226B2 (hr)
EP (2) EP2398488B1 (hr)
JP (2) JP5916622B2 (hr)
CN (3) CN107184954A (hr)
AU (1) AU2010337822B2 (hr)
BR (1) BR112012016459B1 (hr)
CA (1) CA2784394C (hr)
CY (1) CY1120975T1 (hr)
DK (2) DK2398488T3 (hr)
ES (2) ES2928900T3 (hr)
HK (2) HK1245667A1 (hr)
HR (2) HRP20221208T1 (hr)
HU (2) HUE040390T2 (hr)
LT (2) LT3536333T (hr)
MX (2) MX349162B (hr)
PL (2) PL2398488T3 (hr)
PT (2) PT3536333T (hr)
SI (1) SI2398488T1 (hr)
TR (1) TR201818858T4 (hr)
WO (1) WO2011080733A1 (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
PL2758183T4 (pl) 2011-09-18 2022-10-10 Bio Plasmar Ltd Biodegradowalne doniczki lub naczynia na żywność
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
CN103169670B (zh) * 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
MX2016001422A (es) * 2013-07-29 2016-10-05 Aizant Drug Res Solutions Pvt Ltd Composicion farmaceutica de fingolimod.
CN105873570A (zh) * 2013-12-23 2016-08-17 奇尼塔有限责任公司 治疗性蛋白质的持续释放储槽式调配物和其用途
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
US20210220428A1 (en) 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3035149A1 (en) * 2016-08-28 2018-03-08 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
MX2019002284A (es) 2016-08-31 2019-09-04 Mapi Pharma Ltd Sistemas de deposito que comprenden acetato de glatiramer.
CN110099677A (zh) * 2016-10-28 2019-08-06 斯皮内特赫拉公司 药物组合物及其用途
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
EP3624815A4 (en) * 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load
US20230256058A1 (en) * 2020-06-29 2023-08-17 Mapi Pharma Ltd. Low burst-release liraglutide depot systems
IL302517A (en) * 2020-11-02 2023-07-01 Simcha Il 18 Inc Variants of interleukin-18 and methods of use
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
EP4285892A1 (en) * 2021-01-29 2023-12-06 Tionlab Therapeutics Depot composition with controlled initial release, and method for preparing same
US11865213B2 (en) 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
AU2022308198A1 (en) 2021-07-06 2024-02-01 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition
WO2024054879A1 (en) * 2022-09-06 2024-03-14 Regents Of The University Of Michigan Biodegradable polymeric particles for delivery of positively charged therapeutic agents

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IT1276690B1 (it) 1995-06-09 1997-11-03 Ira Srl Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
EP1128839A4 (en) 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
CN100360180C (zh) 2000-01-20 2008-01-09 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
CA2398277C (en) 2000-06-07 2013-09-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for protecting cns cells from glutamate toxicity
US6835711B2 (en) 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
HUP0401079A3 (en) 2001-07-10 2008-04-28 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
CA2462459C (en) * 2001-10-03 2007-12-18 Jack L. Strominger Copolymers for suppression of autoimmune diseases, and methods of use
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1398584A (zh) * 2002-07-15 2003-02-26 裴福兴 一种bFGF－PLGA缓释微球及其制备方法和用途
KR101137785B1 (ko) 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20060276390A1 (en) * 2003-07-31 2006-12-07 Yeda Research And Development Co. Ltd. Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
NZ546379A (en) * 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
WO2005070332A1 (en) 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
MXPA06010043A (es) 2004-03-01 2007-03-07 Peptimmune Inc Metodos y composiciones para el tratamiento de enfermedades autoinmunologicas.
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2008075365A1 (en) 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
US8138201B2 (en) * 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
JP2011529078A (ja) 2008-07-25 2011-12-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 自己免疫疾患を治療および予防するための方法および組成物
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Also Published As

Publication number Publication date
CA2784394C (en) 2016-12-13
EP3536333A1 (en) 2019-09-11
JP2013516403A (ja) 2013-05-13
US20120015891A1 (en) 2012-01-19
ES2928900T3 (es) 2022-11-23
LT3536333T (lt) 2022-11-10
HRP20221208T1 (hr) 2022-12-09
BR112012016459B1 (pt) 2020-01-14
CN107184954A (zh) 2017-09-22
JP2016074696A (ja) 2016-05-12
WO2011080733A1 (en) 2011-07-07
EP2398488A4 (en) 2014-06-11
MX2012007760A (es) 2012-08-01
MX349162B (es) 2017-07-14
MX2020003805A (es) 2022-05-05
EP2398488A1 (en) 2011-12-28
AU2010337822A1 (en) 2012-07-12
ES2699692T3 (es) 2019-02-12
LT2398488T (lt) 2019-01-25
US8796226B2 (en) 2014-08-05
CA2784394A1 (en) 2011-07-07
SI2398488T1 (sl) 2019-02-28
TR201818858T4 (tr) 2019-01-21
AU2010337822B2 (en) 2016-03-17
HRP20182076T1 (hr) 2019-02-08
HUE040390T2 (hu) 2019-03-28
CY1120975T1 (el) 2019-12-11
HK1245667A1 (zh) 2018-08-31
EP2398488B1 (en) 2018-11-14
BR112012016459A2 (pt) 2017-10-03
HUE060304T2 (hu) 2023-02-28
PL3536333T3 (pl) 2022-12-05
DK2398488T3 (en) 2019-01-28
CN102686235A (zh) 2012-09-19
PL2398488T3 (pl) 2019-03-29
PT3536333T (pt) 2022-11-11
CN107661490A (zh) 2018-02-06
CN107661490B (zh) 2021-12-31
PT2398488T (pt) 2018-12-20
JP5916622B2 (ja) 2016-05-11
EP3536333B1 (en) 2022-08-03
HK1244430A1 (zh) 2018-08-10

Similar Documents

Publication Publication Date Title
HRP20182076T1 (hr) Sustav s kontroliranim otpuštanjem koji obuhvaća glatiramer acetat
DK2658573T3 (da) Ekspressionssystemer
DK2630513T3 (da) Positionsbestemmelsessystem
DK2585140T3 (da) Autoinjektor
BR112013008072A2 (pt) autoinjetor
BR112013008401A2 (pt) autoinjetor
DK2536452T3 (da) Autoinjektor
DK2585137T3 (da) Autoinjektor
EP2783338A4 (en) USE OF MOBILE DIGITAL COUPONS AT THE POINT OF SALE
DK2549029T3 (da) Platformsystem
DK2654833T3 (da) Autoinjektor
DK2637954T3 (da) Containerhåndteringssystem
DK2654842T3 (da) Autoinjektor
DK2425742T3 (da) Eftermonteringssystem til hylde
FI20106092A0 (fi) Jarrutuslaitteisto
EP2578998A4 (en) NAVIGATION SYSTEM
BR112013015785A2 (pt) autoinjetor
DK2423428T3 (da) Forseglingssystem
BR112013009679A2 (pt) peptídeo
DK2571792T3 (da) Transportanlægsenhed
FI8898U1 (fi) Hyllyjärjestelmä
FIU20100129U0 (fi) Säilytysjärjestelmä
TH1201003018B (th) ออกซินทอมอดูลินเพปไทด์แอนะล็อก
FI20110228L (fi) Sosiaalinen hälytysjärjestelmä
FIU20100421U0 (fi) Järjestelmä irtotavaran purkamiseksi laivasta